Lyon: The stock price of Sino Pharmaceutical Group (01093.HK) is weak, but the fundamentals are good and business development is in line with expectations.

Wisdom Finance App learned that Lyon released a research report stating that the stock price performance of Shiyao Group (01093.HK) was weak, mainly due to market panic over the 11th round of volume-based procurement policy (VBP) measures announced by the National Medical Insurance Bureau today, especially the requirement that each medical institution's annual demand for each variety should not be less than 80% of the average usage for the years 2023-2024. The bank stated that compared to previous years, the volume-based procurement requirements remain unchanged, and as the VBP policy begins to introduce optimization measures, the market expects the requirements to become more relaxed. The bank stated that for Shiyao Group, no products were included in the 11th round of VBP, believing that the company's fundamentals are good and its business development progress is in line with expectations.